> ChemoCentryx has bowed to the inevitable and withdrawn its $57.5 million IPO. Report
> Debiopharm and Pharmaleads SAS have inked an exclusive license agreement for the development, registration and commercialization of a small molecule called Debio 0827 or PL37, about to enter phase I clinical trials. Release
> Eisai Corporation of North America announced today that the FDA approved BANZEL (rufinamide) for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. Release
> Codexis and Dyadic International announced a license agreement covering use of Dyadic's C1 expression system for large-scale production of enzymes in certain fields including biofuels and chemical and pharmaceutical intermediate production. Release
> Eli Lilly and United Therapeutics have inked a deal to commercialize the active ingredient in Cialis--tadalafil--for pulmonary arterial hypertension. Report
> Indian drugmakers are feeling a bit paranoid these days. Big Brother, a.k.a. the FDA, is looking over their shoulders, and they're not happy about it. Report
> Well, it's not good news for those long-suffering cholesterol meds Vytorin and Zetia--but at least it's not more bad news. The two drugs, which have seen new scrips fall and fall again since less-than-stellar research news first hit in January, may finally be bottoming out. Report
> Can it be that Merck is going out looking for unexpected cardiovascular side effects? The drugmaker is preparing to launch a massive trial of its diabetes med Januvia, specifically to check for potential heart problems. Report
> We've been talking a lot about drug sales in the developing world lately, as Big Pharma eyes markets such as Brazil, China and India--the so-called BRIC countries--to make up for stalling sales in the U.S. This week's Economist comes to the party, taking a look at America's declining contribution to pharma profits, and just how developing countries might help take up the slack. Report
And Finally... Newcastle University is establishing a medical and biotech hub in Malaysia. Article